AbbVie to Acquire TeneoOne and Lead Asset for Multiple Myeloma Treatment
AbbVie has exercised its right to acquire TeneoOne, along with its lead immunotherapeutic asset for the potential treatment of multiple myeloma.
On June 24, 2021, AbbVie and Teneobio, an affiliate of Teneobio, Inc., announced that AbbVie has exercised its exclusive right to acquire TeneoOne, and TNB-383B, a B-cell maturation antigen (BCMA)-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM).
AbbVie and TeneoOne had entered a strategic transaction in February 2019 to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. AbbVie exercised its acquisition right based on an interim analysis of an ongoing Phase I study.
The interim results from the ongoing Phase I study demonstrated an objective response rate of 79%, very good partial response or better of 63%, and complete response of 29% at doses ≥40 mg.
"Since the beginning of this partnership, we have been encouraged by the potential of TNB-383B as a promising new therapy for multiple myeloma, and our analysis of the Phase [I] data to date has allowed us to make this decision with confidence," said Michael Severino, MD, vice-chairman and president, AbbVie, in a company press release. "While other BCMA and CD3 bispecific therapies require weekly administration, the recommended Phase [II] dose of TNB-383B will investigate infrequent dosing of every [three] weeks for intravenous administration, which is an important treatment factor for people living with multiple myeloma."
"Our aim in developing TNB-383B and our T-cell redirecting anti-CD3 platform is to maximize the therapeutic window of a class of therapeutic molecules that have been clinically challenged by dose-limiting toxicities," said Roland Buelow, CEO of Teneobio, Inc., in the press release. "AbbVie recognized the potential of Teneobio's platform and shared our vision to assess its clinical validation. The clinical data support the unique features of TNB-383B and our T-cell redirecting CD3 platform. We are confident that AbbVie is the right partner to rapidly develop TNB-383B with the ultimate goal to bring this potential new therapy to myeloma patients in need."
Source: AbbVie
